Ge Healthcare Technologies Inc Stock Price, News & Analysis

GE HealthCare (Nasdaq: GEHC) will supply more than 300 CT scanners to public hospitals across all 38 provinces of Indonesia under the multi‑year SIHREN program, targeting installation by 2028 to expand diagnostic access for more than 280 million Indonesians.

The competitively awarded contract follows World Bank procurement rules and supports NCD management, maternal health and pandemic resilience. GE HealthCare is expanding local capability via a Bogor production facility, recent awards for 10 1.5T MR systems (early 2025), and the RITE training hub (2024) to build workforce skills and technology transfer.

GE HealthCare (Nasdaq: GEHC) and Mayo Clinic launched GEMINI-RT, a research collaboration announced on December 3, 2025 to advance personalized radiation therapy by integrating imaging, AI, and patient monitoring across the cancer care continuum.

The initiative focuses on four pillars: Automation, Predictive Oncology, Multi‑modal Therapies, and Connected Care, and will be based at Mayo Clinic’s Rochester campus. GEMINI-RT aims to streamline data-driven planning, reduce clinician burden, model individual patient journeys, and explore combining radiation with targeted therapies and home monitoring.

University of Rochester Medical Center and GE HealthCare (Nasdaq: GEHC) launched a seven-year Care Alliance on December 3, 2025 to standardize imaging and monitoring across UR Medicine.

The program includes upgrades and new MRI, Aurora SPECT/CT, dual-energy CT, LOGIQ E10 ultrasound, on-device AI, a Continuum+ software upgrade path, plans for an on-site cyclotron to produce radiopharmaceutical tracers, and system-wide Carescape ONE monitoring powered by Carescape Canvas.

GE HealthCare (Nasdaq: GEHC) announced expanded collaboration with NVIDIA at RSNA 2025 to embed NVIDIA accelerated computing across CT, MRI, ultrasound, cardiac, and mammography solutions.

Key highlights include Photonova Spectra PCCT (510(k) pending) claiming up to 50x more data throughput, SIGNA Bolt and SIGNA Sprint MRI platforms using NVIDIA GPU-accelerated reconstruction, Pristina Recon DL for 3D mammography, and Vivid Pioneer ultrasound with dual professional NVIDIA GPUs. Early-stage autonomous X-ray and ultrasound concepts are being explored with NVIDIA Isaac and Holoscan.

GE HealthCare (Nasdaq: GEHC) unveiled Allia Moveo, a compact, cable-free C-arm image-guiding solution for the interventional suite designed to increase mobility, patient access and workflow efficiency. The system features a slim, wide-bore C-arm intended to enable cone beam CT (CBCT) for a broader patient range, ergonomic controls accessible from nearly any position, AI-powered and augmented guidance tools, and SmartMove to reposition and restore the C-arm at the press of a button. Allia Moveo supports multi-modality integrations and is FDA 510(k) pending. Availability may vary by region; GE HealthCare will showcase the platform at RSNA 2025 (booth #7334).

GE HealthCare (Nasdaq: GEHC) will present at RSNA 2025 on November 30, 2025, showcasing more than 40 technology innovations across imaging devices, radiopharmaceuticals, cloud and AI solutions.

Key disclosures include $3B invested in R&D since 2022; the FDA-approved PET MPI agent Flyrcado (flurpiridaz F 18) with CMS traditional pass-through effective Apr 1, 2025; Photonova Spectra photon-counting CT (510(k) pending); next‑gen SIGNA MRI systems (510(k) pending); and a claim of 100 FDA-authorized AI-enabled solutions.

GE HealthCare (Nasdaq: GEHC) announced on November 30, 2025 the unveiling of next‑generation SIGNA MRI technology and submitted 510(k) filings to the U.S. FDA seeking clearance. New systems include SIGNA Bolt (a 3.0T high‑field wide‑bore system) and SIGNA Sprint with Freelium (a 1.5T, purposefully helium‑free/ventless design with <1% helium usage). Both run on the AI‑driven SIGNA One workflow platform aimed at improving exam efficiency, patient setup, and imaging reconstruction. The announcement emphasizes sustainability, installation flexibility, and AI‑enabled workflow automation while noting regulatory clearance is pending.

GE HealthCare (Nasdaq: GEHC) announced FDA Premarket Authorization for Pristina Recon DL, a deep learning 3D mammography reconstruction application that enhances image sharpness, reduces artifacts, and preserves patient dose. The technology uses two sequential deep learning models plus iterative reconstruction and NVIDIA RTX acceleration to deliver fast, high-fidelity DBT images in the exam room. Clinical validation cited a 99.1% radiologist preference for overall image quality and improved detection of microcalcifications and masses. The feature is upgradable on Pristina Via and supports workflow and patient‑experience improvements.

GE HealthCare (Nasdaq: GEHC) introduced Genesis™ Radiology Workspace, a cloud-first radiology solution built to unify the user experience, streamline workflows, and enable diagnosticians to read from virtually anywhere.

The platform centers on Genesis™ View (510(k) pending; not available for sale in the United States), a zero-footprint viewer that offers high-performance 2D/3D visualization, embedded AI tools, FHIRcast interoperability, and direct access to Advanced Visualization apps. The suite integrates with GE HealthCare’s Genesis cloud portfolio and will be shown at RSNA 2025 (Nov. 30–Dec. 4) in Chicago, booth 7334.